InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025)

InMed Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at $3.8 million for Q2 2025.

• On a quarterly basis, Other financing activities rose 376907800.0% year-over-year to $3.8 million in Q2 2025; TTM through Jun 2025 was $8.1 million, a 12736.07% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 55.87% from the prior year.
• Other financing activities climbed to $3.8 million in Q2 2025 per INM's latest filing, from $2.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $10.2 million in Q4 2022 and bottomed at -$63697.0 in Q1 2023.
• The 5-year median for Other financing activities is $454089.5 (2021), against an average of $1.5 million.
• Across the five-year window, Other financing activities slumped 100.13% in 2023 and jumped 376907800.0% in 2025, its largest moves.
• Year by year, Other financing activities stood at $179118.0 in 2021, then soared by 5579.55% to $10.2 million in 2022, then plunged by 100.01% to -$646.0 in 2023, then jumped by 61423.99% to $396153.0 in 2024, then jumped by 851.42% to $3.8 million in 2025.
• Per Business Quant, the three latest INM Other financing activities figures stand at $3.8 million (Q2 2025), $2.9 million (Q1 2025), and $396153.0 (Q4 2024).